Pfizer begins first human tests of potential arthritis and lupus drug
NCT ID NCT07235163
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called PF-08065010 in 100 healthy adults aged 18 to 65. The goal is to check its safety and how the body processes it, as a first step toward possibly treating rheumatoid arthritis and lupus. Participants receive either the drug or a placebo as a shot or IV, with frequent monitoring over several months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-08065010
What this could lead to
If successful, this could pave the way for a new treatment option for rheumatoid arthritis and lupus.
What could go wrong
This is an early Phase 1 safety study in healthy people, not patients. The drug may not work or could have side effects in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••